Bioequivalent study for a generic product of fluconazole capsule 50 mg
- Conditions
- Certain infectious and parasitic diseases
- Registration Number
- KCT0003344
- Lead Sponsor
- Pfizer Pharmacueticals Korea
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 28
1. Healthy male or female subjects between 19 and 55 years.
2. No clinically relevant abnormailities identified by blood pressure, pulse rate, 12-lead ECG, physical examination, and laboratory tests.
3. Femail subjects without evidences of pregnancy.
4. Body mass index of 17.5 to 30.5 kg/m2; and a total body weight over 50 kg.
5. A personally signed and dated informed consentt document indicating that the subject has been informed of all pertinent aspects of the trial.
6. Subjects who are willing and able to comply with scheduled visits, treatemtn plan, laboratory tests, and other trial procedures.
1. Present illnesses or histories of clinically significant diseases.
2. Any gastrointestinal disorders affecting drug absorption.
3. A positive urine durg screen.
4. Regular alcohol consumption exceeding 21 units/week (14 units/week for females) within 6 months of screening.
5. Treatment with an investigational drug within 3 months or 5 half-lives (whichever is longer) prior to the first dose of trial medications.
6. Systolic blood pressure >= 140 mmHg or diastolic blood pressure >= 90mmHg.
7. QTc interval > 450 msec or QRS interval > 120 msec in 12-lead ECG.
8. AST or ALT >= 2 ULN, or total bilirunin >= 2.0 mg/mL.
9. Female subjects of childbearing potential or male subjects who are not willing to use appropriate contraception during the study and for at least 28 days which is longer after the final study drug administration. Femail subjects who are possibly pregnant or breastfeeding.
10. Use of prescription or nonprescription drugs, dietary supplements within 7 days or 5 half-lives (which is longer) prior to the first dose of trial medications.
11. Use of CYP inducers or inhibitors within 1 month of screening. (Herbal supplements must be discontinued before 28 days prior to the first dose of trail meidations.)
12. Blood donations over 1 pint (500 mL) within 60 days prior to dosing. (except plasmapheresis)
13. History of sensitivity to heparin or heparin-induced thromnocytopenia.
14. Any positive result of HBsAg, anti-HCV, anti-HIV, HIV ag, and RPR.
15. Subject unwilling or unable to comply with the lifestyle guidelines.
16. Employees or their family of trial sites, bioanalytical laboratories, contract research organizations, and sponsors.
17. Subjects whose medical or psychologic status considered ineligible by investigators, suicidal intent or suicide attemps.
18. Sensitivity to investigational products, ingredients, or azole derivatives.
19. Galactose intolerance, Lapp lactose deficiency, or glucose-galactose malansorption.
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Area under concentration-time curve;Maximum plasma concentration
- Secondary Outcome Measures
Name Time Method Area under concentration-time curve to infinity;Time to maximum plasma concentration;Terminal half-life